Stockreport

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

Xencor, Inc.  (XNCR) 
Last xencor, inc. earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.xencor.com/investor-relations
PDF -- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC ---- 25% overall response rate (ORR) observed within the target dose range ---- First dos [Read more]